Every 8-K that TNF Pharmaceuticals, Inc. (TNFA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TNFA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNFA filings page.
Q/C Technologies, Inc. reported that its Audit Committee dismissed Stephano Slack LLC as its independent registered public accounting firm on March 9, 2026, and appointed Grassi & Co., CPAs, P.C. as the new auditor for the year ended December 31, 2025.
The prior auditor’s reports for 2023 and 2024 contained a going concern paragraph noting net loss and negative operating cash flows for 2024 that raised substantial doubt about the Company’s ability to continue as a going concern, with no related adjustments recorded. The Company states there were no disagreements or reportable events with Stephano Slack, and it has obtained a letter from the former auditor addressed to the SEC agreeing with these disclosures.
Q/C Technologies, Inc. entered into a 12‑month consulting agreement with Chelsea Voss on January 16, 2026. She will provide services such as evaluating companies, analyzing technologies and operations, advising on potential acquisitions, and other consulting support requested by the company.
As compensation, Q/C Technologies will pay Ms. Voss $12,500 per month (or $150,000 annually) and grant her 212,500 restricted stock units that vest in four substantially equal quarterly installments, as well as stock options for up to 212,500 shares of common stock with an exercise price per share equal to the greater of $5.097 or the fair market value on the grant date, also vesting quarterly over the term.
The company also appointed Ms. Voss to its board of directors, highlighting her background in large‑scale machine learning and AI systems, including work on GPT‑4, ChatGPT, DALL·E 2, and Codex, and prior software engineering roles at several technology companies.
Q/C Technologies, Inc., formerly TNF Pharmaceuticals, Inc., has formally changed its corporate name to Q/C Technologies, Inc. effective September 22, 2025. The company also changed its Nasdaq trading symbol from “TNFA” to “QCLS” before the market opened on September 25, 2025.
The name change was implemented through a Certificate of Amendment to the Certificate of Incorporation under Section 242 of the Delaware General Corporation Law, which did not require stockholder approval. The company states that the name change does not affect the rights of its security holders and that its CUSIP number remains the same. Press releases announcing the name change and ticker symbol change were issued on September 24 and 25, 2025.
TNF Pharmaceuticals, Inc. reported closing a set of financing and restructuring transactions, including a private placement and an acquisition. The company sold 7,000 shares of Series H Convertible Preferred Stock, each with a stated value of $1,000, initially convertible into up to 1,400,000 shares of common stock at $5.00 per share, together with warrants to purchase up to 1,400,000 additional common shares at an exercise price of $5.00 per share.
TNF also agreed to acquire 100% of the membership interests of LPU Holdings LLC, paying in Series I Convertible Preferred Stock that is convertible into 747,362 shares of common stock, subject to conversion limits. The company filed new certificates of designations for the Series H and Series I preferred stock and amended the Series F and Series F‑1 preferred terms to extend their maturity to March 2, 2027 and remove amortization payments. A press release announcing the private placement closing was furnished as an exhibit.
TNF Pharmaceuticals, Inc. filed an amended current report to add full contract exhibits related to its previously disclosed acquisition of LPU Holdings LLC. Under a Membership Interest Purchase Agreement, the company agreed to acquire 100% of the membership interests of LPU from its members. As consideration, TNF Pharmaceuticals delivered shares of its Series I Convertible Preferred Stock that are convertible into 747,362 shares of common stock, subject to conversion limits in the Series I certificate of designations.
The filing also attaches a Support Agreement with the LPU sellers, a Registration Rights Agreement providing for future registration of securities, and a License Agreement among TNF Pharmaceuticals, LPU, and LightSolver Ltd. This amendment states it is solely to file these exhibits and does not change any other disclosure from the original report.
TNF Pharmaceuticals disclosed several financing and registration matters tied to newly issued preferred stock and related agreements. The company will file a resale registration statement to register 100% of the Series I conversion shares shortly after the acquisition closing and to register milestone securities promptly after each milestone, with effectiveness targets of 60 days after filing (90 days if the SEC conducts a full review). The Series I Registration Rights Agreement imposes liquidated damages if the company fails to file, obtain effectiveness, or maintain the registration. The document describes a mechanism that increases the Maximum Issuance of common stock upon conversions of certain existing preferred or exchanged securities by an incremental 0.1999 shares per share converted. Separately, under a consulting agreement the company agreed to pay a monthly $15,000 retainer and issue 15,433 advisory shares to Palladium, which will be included in any resale registration statement.